Prolactin Blood Test Explained: What It Measures and Why It's Ordered

This page is for educational purposes only and is not medical advice; consult a licensed physician about any laboratory result, symptom or medication. Nothing here interprets an individual test value, and no reference ranges are offered as guidance — reference intervals are assay-specific and belong to the laboratory and the clinician who ordered the test.

What prolactin is and where it comes from

Prolactin is a polypeptide hormone secreted mainly by lactotroph cells of the anterior pituitary gland. Unlike most pituitary hormones, its release is held under tonic inhibitory control by hypothalamic dopamine travelling down the pituitary stalk, which is why interference with dopamine signalling — pharmacological or structural — is a recurring theme in the clinical literature on raised prolactin. Reviews of prolactin measurement describe the hormone circulating in more than one molecular form, including monomeric prolactin and high-molecular-weight complexes, a heterogeneity that directly shapes how assays behave (PMID 17315036). The same technology review noted that immunoassays detect immunoreactive prolactin, which is not necessarily identical to the biologically active fraction (PMID 17315036).

What the prolactin blood test measures

In routine practice the analyte is total immunoreactive prolactin in serum or plasma, drawn by standard venepuncture and analysed on automated platforms. Technology reviews describe modern prolactin measurement as dominated by two-site (sandwich) immunometric assays using chemiluminescent or similar labels, which replaced older competitive radioimmunoassays (PMID 17315036). Results are reported in mass units or international units depending on the platform and calibrator, and the same review emphasised that harmonisation across assays and standards remains an ongoing laboratory issue (PMID 17315036). Comparable standardisation problems have been described for other pituitary hormone immunoassays; a review of laboratory measurement of growth hormone set out how calibrator choice, antibody specificity and isoform recognition can make numerical results method-dependent (PMID 15530455).

Because of this, published method reviews caution that a prolactin value is not a free-standing number: it is the output of a specific assay, against a specific standard, in a specific sample (PMID 24094642). Laboratories may also run additional steps — most commonly polyethylene glycol precipitation — to report a post-treatment prolactin value alongside the total, a workflow described at length in the macroprolactin literature (PMID 24094642).

Why clinicians order a prolactin test, as described in the literature

Published sources describe prolactin testing being requested in several distinct clinical contexts:

• Suspected hyperprolactinaemia syndromes. Reviews of prolactin determination frame the test as the entry point for investigating galactorrhoea, menstrual disturbance, reduced fertility and hypogonadal symptoms, with the laboratory result then triaged for interference before imaging is considered (PMID 24094642).
• Pituitary and hypothalamic disease. A 2025 study measured serum prolactin concentrations in patients with childhood-onset craniopharyngioma, a sellar and suprasellar tumour, illustrating why prolactin is assessed when hypothalamic–pituitary structures are known or suspected to be involved (PMID 40481916).
• Drug monitoring in psychiatry. A review of clinical guidelines examined what existing recommendations said about prolactin monitoring in people treated for psychosis, and the authors reported substantial inconsistency between guidelines on whether, when and how often prolactin should be measured (PMID 18477625).
• Clarifying borderline elevations. A 2024 study evaluated the diagnostic utility of the prolactin decrease rate — comparing sequential samples rather than relying on a single draw — in patients with mild hyperprolactinaemia (PMID 39552974).
• Research into low values. Groups studying hypoprolactinaemia have used prolactin measurement to define cohorts with unusually low concentrations and then compared their metabolic characteristics with controls (PMID 35906342).

What published studies associate with high prolactin values

The best-documented non-tumoural cause in the literature is medication. Two published case reports described olanzapine-induced hyperprolactinaemia, with the authors reporting elevated prolactin concentrations in patients receiving the antipsychotic and discussing the dopamine-blockade mechanism behind the finding (PMID 31417404). The guideline review in psychosis care similarly treated antipsychotic-associated prolactin elevation as a recognised, monitorable consequence of treatment, while reporting that guideline advice on monitoring frequency diverged considerably (PMID 18477625).

A second, frequently overlooked source of a high number is analytical rather than physiological. Reviews of macroprolactin describe high-molecular-weight prolactin–immunoglobulin complexes that are detected by immunoassays but are considered to have limited bioavailability, so that affected patients can present with a raised total prolactin and few or no classical symptoms (PMID 24094642). A 2019 report on serum prolactin overestimation set out how such analytical overestimation can propagate into misdiagnosis if the result is taken at face value (PMID 31294082).

Researchers have also asked whether macroprolactinaemia is metabolically inert. A 2019 study compared cardiometabolic risk factors in young women with macroprolactinaemia against comparison groups and reported differences in measured risk markers between the groups (PMID 30845340). That observational work does not establish causation, and the authors framed it as a reason for further study rather than a management rule (PMID 30845340).

Finally, sampling conditions matter. The 2024 prolactin decrease rate study was premised on the observation that a single elevated value in mild hyperprolactinaemia may not be reproducible, and the researchers assessed whether the change between sequential samples carried diagnostic information (PMID 39552974).

What published studies associate with low prolactin values

Low prolactin has received far less attention than high prolactin, but a small body of work has examined it directly. A 2022 study characterised the cardiometabolic profile of young women with hypoprolactinaemia and reported that the hypoprolactinaemic group differed from comparison participants across measured metabolic variables (PMID 35906342). A 2024 pilot study extended the question to men, and the researchers reported increased cardiometabolic risk markers in men with hypoprolactinaemia relative to controls (PMID 39456268). Both were small, cross-sectional and exploratory; the 2024 report was explicitly labelled a pilot study by its authors (PMID 39456268). Low prolactin has also been measured in the context of structural hypothalamic–pituitary disease, as in the 2025 craniopharyngioma cohort where serum prolactin concentrations were assessed in childhood-onset disease (PMID 40481916).

Assay and interpretation caveats described in the literature

Prolactin is unusual among common endocrine tests in having several well-documented ways to generate a misleading number in both directions.

The hook effect deserves a plain-language note because it moves the result in the counter-intuitive direction. In sandwich immunoassays, extremely high antigen concentrations can saturate both capture and detection antibodies so that the measured signal falls; the 2022 investigation asked whether this artefact still exists on contemporary platforms and reported on the circumstances in which laboratories should consider sample dilution (PMID 35793045). Because macroprolactin pushes results up and the hook effect can push them down, review authors have argued that the laboratory, not only the clinician, carries part of the interpretive responsibility for prolactin (PMID 24094642).

Reported harms and misclassification risks: What Studies Report

The prolactin blood test itself is a venepuncture, and the published concerns in this literature relate to what follows a misread result rather than to the draw. The 2019 overestimation report framed the downstream problem as misdiagnosis — investigations and labels applied on the basis of a number that did not reflect bioactive monomeric prolactin (PMID 31294082). Macroprolactin reviews made the same point, describing unnecessary imaging and treatment as consequences of unscreened elevations (PMID 24094642).

On the drug side, the two published olanzapine case reports described hyperprolactinaemia arising during antipsychotic treatment and the clinical reasoning used in each case (PMID 31417404). The guideline review reported that recommendations for prolactin monitoring in psychosis were inconsistent across the documents the authors examined, which they treated as a gap in standardised care rather than evidence against monitoring (PMID 18477625). Decisions about any prescribed medication belong to the prescriber.

What a single prolactin result does not settle

Across these papers, several limits recur. Observational cardiometabolic studies in hypoprolactinaemia and macroprolactinaemia were small and cross-sectional, so associations reported in them cannot establish that prolactin concentrations caused the metabolic differences observed (PMID 35906342, PMID 30845340). Case reports describe individuals, not populations (PMID 31417404). Analytical reviews stress that a number must be read against the method that produced it (PMID 17315036). And at least one study exists specifically because single measurements in the mildly elevated range were not considered reliable enough on their own (PMID 39552974). Interpretation of any individual prolactin result — including whether repeat testing, macroprolactin screening, dilution or imaging is appropriate — rests with the clinician who ordered it.

References

• Technology insight: measuring prolactin in clinical samples (Nature Clinical Practice Endocrinology & Metabolism, 2007)
• Determination of prolactin: the macroprolactin problem (Best Practice & Research Clinical Endocrinology & Metabolism, 2013)
• Laboratory measurement of growth hormone (Clinica Chimica Acta, 2004)
• Serum prolactin overestimation and risk of misdiagnosis (Endocrinology, Diabetes & Metabolism, 2019)
• Prolactin immunoassay: does the high-dose hook effect still exist? (Pituitary, 2022)
• Diagnostic Utility of the Prolactin Decrease Rate in the Diagnosis of Mild Hyperprolactinemia (Cureus, 2024)
• Current guidelines and their recommendations for prolactin monitoring in psychosis (Journal of Psychopharmacology, 2008)
• Olanzapine-Induced Hyperprolactinemia: Two Case Reports (Frontiers in Pharmacology, 2019)
• Cardiometabolic risk factors in young women with macroprolactinaemia (Endokrynologia Polska, 2019)
• Cardiometabolic profile of young women with hypoprolactinemia (Endocrine, 2022)
• Increased Cardiometabolic Risk in Men with Hypoprolactinemia: A Pilot Study (Biomolecules, 2024)
• Prolactin serum concentrations in childhood-onset craniopharyngioma patients (Journal of Endocrinological Investigation, 2025)